Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05459688 · ClinicalTrials.gov registry record · Phase 2

Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124

A Phase 2 study of Hypertension, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
175
Enrollment target
20
Study locations

NCT05459688 is a Phase 2 study of Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 175 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05459688, a Phase 2 study of Hypertension, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
175 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.

Conditions Studied

Hypertension

Interventions

  • DRUG CIN-107

Study Locations (20)

Florida

  • Research Site - Clearwater
  • Research Site - Doral
  • Research Site - Hialeah
  • Research Site - Hollywood
  • Research Site - Lake Worth
  • Research Site - Miami
  • Research Site - Miami
  • Research Site - Pembroke Pines
  • Research Site - Winter Haven

California

  • Research Site - Huntington Park
  • Research Site - Lincoln
  • Research Site - Los Angeles
  • Research Site - Northridge
  • Research Site - Oceanside
  • Research Site - Panorama City
  • Research Site - Van Nuys

Illinois

  • Research Site - Addison
  • Research Site - Chicago
  • Research Site - Morton

Alabama

  • Research Site - Saraland

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2022-04-06
Est. Completion 2023-11-07
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05459688

The ClinicalTrials.gov registry entry for NCT05459688 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (95% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which CIN-107 is the first listed.

NCT05459688 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT05459688 about?

NCT05459688 is a clinical study titled "Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124". This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at clinical sites that have part...

What is the current status of trial NCT05459688?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2022-04-06. Estimated completion is 2023-11-07.

What conditions does trial NCT05459688 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT05459688?

The interventions under investigation include: CIN-107 (DRUG).

Who is sponsoring clinical trial NCT05459688?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05459688 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.